Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Antibody-drug conjugates (ADCs) are a class of innovative biopharmaceutical drugs, which,
via their antibody (mAb) component, deliver and release their potent warhead (aka. payload) …

Antibody-drug conjugates (ADCs) are a promising class of cancer biopharmaceuticals that
exploit the specificity of a monoclonal antibody (mAb) to selectively deliver highly cytotoxic …

The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial
recent developmental investment and subsequent drug approvals over the past 6 years. In …

The treatment of cancer patients has dramatically changed over the past decades with the
advent of monoclonal antibodies, immune-checkpoint inhibitors, bispecific antibodies, and …

Despite significant advances in the treatment of cervical, ovarian, and uterine cancers with
the approvals of checkpoint and PARP inhibitors into standard treatment, patients with …

Simple Summary Antibody–drug conjugates (ADCs) are a growing class of therapies that
aim to delivery therapy more efficiently, with fewer side effects, than conventional …